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Background: In the current two decades, dyslipidemia and increased blood glucose as metabolic abnormalities are
the most common health threats with a high incidence among HIV/AIDS patients on antiretroviral (ARV) treatment.
Scientific investigations and reports on lipid and glucose disorders among HIV infected communities are
inadequate especially in those developing such as Malaysia. This cross-sectional survey was mainly aimed to
evaluate the prevalence of metabolic abnormalities and associated risk factors among HIV infected population
patients on ARV medication.
Methods: In a single reference health center in Malaysia, 2739 adult HIV positive patients on antiretroviral therapy
(ART) were studied cross-sectionally using medical records. Besides demographic variables and associated health
disorders, those factors which can change the lipid and glucose levels were collected. Logistic Regression was used
to find the potential risk factors (p < 0.05).
Results: Majority of the studied population were male (81.1%) and aged between 30–49 (68.6%). Mean CD4 count
was 474.25 (cells/mm3) while undetectable RNA viral load was common among 83.3 (%) of subjects. Among 1,583
patients with the recent blood lipid and glucose tests, increased levels of triglyceride (TG) and total cholesterol (TC)
were frequently prevalent in half of the population as 59 (%) and 54.2 (%) while 28.7 (%), 35.1 (%) and 38.2 (%) had
declined level of high-density lipoprotein (HDL), raised low-density lipoprotein (LDL) and fasting plasma glucose
(FPG) which were less common. Dyslipidemia was common in 82.3 (%) of the subjects. Notably, medication with
protease inhibitor (PI) was a potential risk for elevated triglyceride (odds ratio (OR) = 2.309, 95% confidence interval
(CI) = 1.605–3.324, P = 0.001), high TC (OR = 1.561, 95% CI = 1.123–2.169, P = 0.008) and low HDL (OR = 1.449,
95% CI = 1.037–2.024, P = 0.029). As lifestyle factor, alcohol consumption results as significant risk factor for raised TG
(OR = 2.653, 95% CI = 1.353–5.202, P = 0.004). Also having hepatitis raised risk of high FPG level (OR = 1.630,
95% CI = 1.197-2.220, P = 0.002) in this sample population.
Conclusions: Dyslipidemia is highly common in Malaysian HIV subjects receiving ARV medication. Lifestyle
modification, changing PI and switch to other ARV regimen can help in reduction of these abnormalities. Also
suitable strategies and plans are necessary to prevent cardiovascular diseases in future.
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Human immunodeficiency virus infection/acquired im-
munodeficiency syndrome (HIV/AIDS) is still consid-
ered as a tragic infectious disease with a high impact
on quality of life among individuals and communities
through the weakening economic and social perfor-
mances which manifests along with poor mental and/or
physical health. Based on the latest report by The Joint
United Nations Programme on HIV/AIDS (UNAIDS), of
34.0 million [31.4 million- 35.9 million] people living with
HIV (PLHIV) at the end 2011 universally [1]. Roughly
81,000 of them [2] were resident in Malaysia which is
a south-east Asian and Upper middle-income country
[3]. Indeed the number of PLHIVs receiving ART as of
December 2011 has increased up to 14,002 [2]. In combat
with HIV/AIDS, there are some progresses in heath con-
dition, quality of life and life expectancy specific after
introduction of antiretroviral therapy (ART) as the only
available medication for control of this disease [4]. How-
ever there has been discovered some adverse effects of
ART in the form of glucose and/or lipid abnormal-
ities which are accounted as cardiovascular risk fac-
tors [5]. The prevalence rates for these disorders are
widely varied ranging from less than 30% for elevated
glucose level [6-9] and 10%-20% for diabetes [10-13],
10-60% for hypercholesterolemia [14-17], 20-70% for
hypertriglyceridemia [15,18,19], 20-40% for low HDL
level [18-20], which are mostly in the form of elevated
triglyceride and low HDL level. In reviews by Carr et al.
(1998), Carr (2000) and Currier et al. (2008) on substan-
tial HIV/AIDS studies they explained other than trad-
itional risk factors and HIV infection itself [21-23]. They
stressed that protease inhibitor (PI) as the third antiretro-
viral (ARV) class also is responsible for these complica-
tions in comparison with other ARV categories such as
nucleoside analog reverse transcriptase inhibitors (NRTI)
and non-nucleoside analog reverse transcriptase inhibi-
tors (NNRTI) and integrase inhibitors (INI).
Generally, the knowledge on blood metabolic abnor-
malities among PLHIV have established mostly in devel-
oped societies including USA [24-26], Europe [27,28],
Australia [29-32] and limited information in developing
[16,19,33,34] and African countries [35-37].
In Asian and specific South east Asian countries
estimated incidence of lipid abnormalities in HIV/AIDS
mostly are reported from Thailand [15,33,38-40] and
India [7,41,42]. They found a very wide range of 5-60%for
high TC, high LDL-c, high TG and low HDL among anti-
retroviral therapy (ART) individuals. Elevated FPG also is
estimated between estimated 27% among Thai [6,38] and
60% in Indian HIV population [7].
The aim of this study is to provide some evidences on
metabolic abnormalities and also associated risk factors
since there is very limited information from HIV/AIDSstudies about these disorders in Malaysia. Moreover,
information from the developed countries cannot be de-
duced to developing societies due to differences in pa-
tient populations, HIV subtypes and lifestyle therefore,
therefore initial and additional studies from developing
countries are required. we assessed the prevalence of
lipid and glucose abnormalities and also associated
the risk factors with each these abnormalities among
Malaysian HIV-infected patients in this study.
Methods
Study population and design
This cross-sectional study was conducted between January
to September 2012 at an Infectious Diseases (ID) clinic
which is also a reference center for HIV and AIDS cases,
located in Selangor, Malaysia. All HIV patients who started
their ARV medication till first January 2012 were listed
based on the computerized medical records. Patients in-
cluded in this study met the following criteria: subjects
must have been on antiretroviral medication at least for
6 months and stable HAART for at least 4 weeks before
study entry, had complete or at least partial lipid and glu-
cose panel performed during this study, equal or more
than 20 years of age and hold Malaysian citizenship. All
death cases were excluded.
Ethical approval was obtained from research ethic
committee/IRB National University of Malaysia and Na-
tional Medical Research Registry (NMRR) Malaysia.
Methods
The collected secondary data from computerized medical
records comprised of demographics (age, gender, and
ethnicity), weight, height and blood pressure, multivitamin
supplementation, ARV medication (NRTIS, NNRTIS, PIs),
those medication history which have effect on lipid and or
glucose level (anti-hypertensive, diuretic, steroid/hormone,
lipid-lowering, anti-hyperglycemic). Also information re-
garding severe opportunistic infections during preceding
six months, medical history as the major current health
problem (tuberculosis, diabetes mellitus, hepatitis, other
liver and renal diseases), alcohol and smoking status in-
cluding the number of subject as current alcohol consumer,
current smoker, and the number of smoked cigarettes per
day were collected.
Fasting blood samples were collected for all studied
subjects. Laboratory testing for blood samples included the
following: fasting lipid profile, fasting plasma glucose, CD4
count, RNA viral load. The laboratory methods for deter-
mination of lipid profiles includes Cholesterol Oxidase-
Peroxidase Amino Phenazone Phenol (CHOD-PAP) for
TC, Accelerator Selective Detergent for HDL,Glycerol-3-
Phosphate Oxidase-Peroxidase Amino Phenazone Phenol
(GPO-PAP) for TG while Low-density lipoprotein (LDL)
was derived from an indirect measurement using the
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esterol was tested using the Cobas Integra 400 Plus
analyzer (Roche Diagnostics Ltd. CH6343, Rotkreuz,
Switzerland). Blood glucose was tested by CD4 was mea-
sured using the FACS Calibur system (Becton Dickinson,
San Jose, CA). HIV RNA Viral load was detected with
Immunophenotyping method using COBAS®AMPLICOR
analyser.
Study definitions
Lipid abnormalities were defined according tothe National
Cholesterol Education Program (NCEP) Adult Treatment
Panel III (ATP III) criteria in 2001 [44] while the American
Heart Association (AHA) and the National Heart, Lung,
and Blood Institute (NHLBI)/Updated NCEP [45,46]
criteria was applied for plasma glucose level. Abnormal-
ities in lipid profile and glucose level (mmol/l) were
classed as TG ≥ 1.7, LDL ≥ 3.36, TC ≥ 5.17, HDL < 1.03
(male) and HDL < 1.30 (female), FPG ≥ 5.6. The defin-
ition of dyslipidemia was according to the occurrence of
one or more of the lipid abnormalities (TG, TC, LDL,
HDL) according to the criteria of the National Choles-
terol Education Program Adult Treatment Panel III.
The CD4 cell counts (cells/mm3) were categorized in
there groups (< 200, 200–499, ≥ 500) according to the
standard of Centre for Disease Control and Preven-
tion [47]. Also HIV RNA load (copies/mL) was classi-
fied using the recommendation from International AIDS
Society-USA Expert Panel [48] references into undetect-




All collected data were analyzed using the statistical
packages for social science (SPSS) for window, version
16.0 [49]. Descriptive data in the form of mean ± stand-
ard deviation (SD) and frequency as the number and
percent (%) were tested. At the beginning, all variables
were tested for normality distribution and then data
cleaning was carried out to weed out the out-of-range
numbers. At the second step of data analysis, based on
the lipid and glucose data (normal and non-normal
groups) the means and percentage distribution of each
variable were calculated using independent sample-t-test
and chi-square test of homogeneity to find significant
differences and associations in variables. As the last step,
the significant risk factors for each metabolic abnormal-
ity using adjusted odd ratios, 95% confidence intervals
and p-values were identified through univariate test as
binary logistic regression with enter method. All binary
analyses were adjusted for age, gender, ethnicity, hyper-
tension, diabetes mellitus, CD4, HIV RNA Load, TC,
TG, LDL, HDL, FPG, alcohol consumption, smoking, liverdisease, medication with agents including ARV (PI),
b-blocker, anti-hyperglycemic. The significance tests were
2-sided, and P values less than 0.05 were considered statis-
tically significant.
Results
Characteristics of study population
Two thousand seven hundred thirty nine patients were
included in the analysis. Dyslipidemia was common in
82.3% of 1583 HIV subjects. Demographics are shown in
Table 1. Most subjects were aged between 40 to 59 years
(55.6%), Chinese (58.8%) and male (81.1%). Mean sys-
tolic (121.31 ± 16.84 mmHg) and diastolic blood pres-
sure (76.83 ± 11.40 mmHg) were in normal range while
19.7% of 2670 subjects were hypertensive. In terms of
ARV medication of all 2637 subjects on ARV treatment
9.3% was receiving PIs and the rest were on the combin-
ation of NRTIs + NNRTIs medication. Small proportions
of subjects were taking anti-hypertension agents (12.2%)
and lipid lowering (18.5%). Majority of HIV study popu-
lation (89.2%) had CD4 cell count ≥ 200 (cells/mm3) and
also 83.3% had a well suppressed and undetectable HIV
viral load as less than 20 (copies/mm3). In relation to
lipid abnormalities, a smaller group of subjects (26.7%)
had the lipid test result only for year 2011 in the time of
data collection. The lipid profile results from year 2012
showed that increased level of triglyceride (> 1.7 mol/ml)
was common among 59.1% of subjects while 35.1% and
54.2% of subjects had higher amount of LDL and total
cholesterol. HDL was lower than normal level in 28.7%
of subjects and 38.2% had high fasting plasma glu-
cose level.
Also in year 2012 till September 10.5% of study popula-
tion were current smoker that 46.5% of smokers reported
more than 20 smoked cigarettes per day. Prevalence of dia-
betes mellitus and Hepatitis are estimated as 12.9% and
14.4% as the most common medical associated condition
among this population. HDL (Mean + SD) level in male
(0.89 + 0.12 mmol/l) was lower than and female (1.08 +
0.17 mmol/l) groups.
Risk factors of high TG
The result of logistic regression analysis (Table 2) re-
vealed that significant risk factors (p < 0.001) for in-
creased TG level were increasing age (OR = 1.018, 95%
CI = 1.008 -1.029), having hypertension (OR = 1.516, 95%
CI = 1.173 - 1.960) and diabetes mellitus (OR = 1.532,
95% CI = 1.150- 2.040), taking b-blockers as antihyper-
tensive agents (OR = 1.668, 95% CI = −1.042), higher
FPG (OR = 1.166, 95% CI = 1.084-1.253), higher CD4
cell count (OR = 1.001, 95% CI = 1.001-1.002), higher
level of TC (OR = 1.281, 95% CI = 1.179 - 1.392) with
following strong risks as low HDL level (OR = 3.585,
95% CI = 2.779-4.625), alcohol taking (OR = 2.653, 95%
Table 1 Characteristics of 2739 HIV infected Subjects on
ARV medications
Characteristics N (%) Mean ± SD
Age 43.06 ± 9.90
20-39 1053 (38.5) 33.56 ± 4.35
40-59 1524 (55.6) 47.22 ± 5.14









Weight (Kg) 2582 (94.27) 61.85 ± 1.21
Height (cm) 215 (7.85) 165.90 ± 9.62
Hypertension* 514 (19.7)
ARV without PI exposure 2392 (90.7)
ARV with PI exposure 245 (9.3)
Supplement§ 384 (14)
B-blocker 70 (2.6)
Other than B-blockerª 263 (9.6)
Diuretic 15 (0.5)
Steroid/Hormone 6 (0.2)
Lipid-lowering agents 508 (18.5)
Anti-Hyperglycaemic agent 191 (7.0)
CD4 (cells/mm3) 2739 (100.0) 474.25 ± 263.02
CD4 < 200 (cells/mm3) 292 (10.8) 122.94 ± 53.78
HIV RNA Load < 20 (copies/mL) 2282 (83.3)
TG ≥ 1.7 (mmol/l) 933(59.1) 3.27 ± 1.92
LDL-C ≥ 3.36 (mmol/l) 555 (35.1) 4.10 ± 0.75
TC ≥ 5.17(mmol/l) 857 (54.2) 6.16 ± 0.95
Low HDL (mmol/l)b 454 (28.7)
FPG ≥ 5.6 (mmol/l) 588 (38.2) 7.08 ± 2.24
Dyslipidaemia 1303 (82.3)
Current alcohol consumer 83 (3.0)
Current smoker 288 (10.5)
Diabetes mellitus 352 (12.9)
Tuberculosis 46 (1.7)
Hepatitis 395 (14.4)
Renal diseases 51 (1.9)
¦ Sarawakian and Sabahan *Blood Pressure ≥ 140/90 (mmHg). §Multivitamin
and vitamin (B complex and C). ª Calcium channel blocker, Alpha blockers
(ACE inhibitors, Angiotensin II receptor antagonists). SD Standard deviation.
bHDL (mmol/l) < 1.03 in male, < 1.30 in female.
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95% CI = 1.605- 3.324).
On the other hand being female (OR = 0.550, 95%
CI = 0.428- 0.707) and Malay (OR = 0.676, 95% CI =
0.464- 0.985), not taking anti- hyperglycemic agents
(OR = 0.603, 95% CI = 0.419- 0.870), higher HDL level
(OR = 0.485, 95% CI = 0.384- 0.612), having hepatitis dis-
ease (OR = 0.576, 95% CI = 0.424- 0.781) significantly re-
duce the risk of hypertriglyceridemia (p < 0.001). CD4
cell, viral load, LDL level and smoking were not associ-
ated with high TG level significantly (p > 0.05).
Risk factors of increased LDL
In this study age, gender, taking ARV agents, medication
with anti-hyperglycemic drugs, diabetes, smoking, alco-
hol consumption, CD4 cell, viral load and FPG level
were not significant risk factor for high LDL (p > 0.05).
Having hypertension (OR = 1.405, 95% CI = 1.093 –1.805)
and diabetes mellitus (OR = 1.532, 95% CI = 1.150–2.040),
higher TC level (OR = 6.468, 95% CI = 5.319–7.866) with
following strong risk as normal HDL level (OR = 2.331,
95% CI = 1.812–2.997) increased the risk (p < 0.05) for high
LDL level (Table 3).
Conversely being Chinese (OR = 0.551, 95% CI = 0.434–
0.701), lower TG level (OR = 0.858, 95% CI = 0.800–0.920),
and having hepatitis disease (OR = 0.592, 95% CI = 0.419–
0.836), significantly protect the subjects from increased
LDL level (p < 0.001).
Risk factors of increased TC
Also the findings of this study (Table 4) confirmed that
that significant risk factors (p < 0.001) for elevated TC
were being older (OR = 1.010 95% CI = 1.000–1.021),
being female (OR = 1.500, 95% CI = 1.163–1.936), hav-
ing hypertension (OR = 1.440, 95% CI = 1.122–1.848),
having viral load level < 20 copies/mm3 (OR = 1.460,
95% CI = 1.093–1.951), higher level of LDL (OR =
6.977, 95% CI = 5.705–8.534), higher TG level (OR =
1.312, 95% CI = 1.220–1.412), having normal HDL level
(OR = 1.867, 95% CI = 1.498–2.327) and treatment with
PI (OR = 1.561, 95% CI = 1.123–2.169).
Interesting that having hepatitis disease (OR = 0.527,
95% CI = 0.387–0.718) significantly protect the subjects
from elevated total cholesterol (p < 0.001). Other factors
including ethnicity, b-blocker, anti-hyperglycaemic medica-
tions, diabetes mellitus, FPG, CD4, smoking and alcohol
consumption did not result in high level of TC significantly
(p > 0.05).
Risk factors of low HDL
Also Table 5 shows that the risk of low HDL level was sig-
nificantly (p < 0.001) related to the factors including being
Chinese (OR = 1.753, 95% CI = 1.187–2.589), taking anti-
hyperglycemic agent (OR = 1.636, 95% CI = 1.152–2.323),
Table 2 Risk factors for increased triglyceride (TG) in 1579 HIV subjects (normal = 646, increased TG = 933) on
ARV medication
Characteristics Normal Increased triglyceride aOR 95.0 C.I. for OR p-value
Mean ± S.D. Mean ± S.D. Lower Upper
N (%) N (%)
Age (per year) 43.41 ± 10.51 45.14 ± 9.36 1.018 1.008 1.029 0.001
Gender
Male 484 (74.9) 788 ( 84.5) 1.00
Female 162 (25.1) 145 ( 15.5) 0.550 0.428 0.707 0.001
Ethnicity
Indian 62 (9.7) 96 (10.3) 1.00
Malay 190 (29.8) 199 (21.4) 0.676 0.464 0.985 0.042
Chinese 386 (60.5) 635 (68.3) 1.062 0.754 1.498 0.730
Hypertension
No 515 (82.4) 670 (75.5) 1.00
Yes 110 (17.6) 217 (24.5) 1.516 1.173 1.960 0.010
ARV medication
Without PI 591 (93.6) 786 (85.9) 1.00
With PI 42 (6.4) 129 (14.1) 2.309 1.605 3.324 0.001
b-Blocker
Not taking 620 (96.0) 872 (93.5)
Taking 26 (4.0) 61 (6.5) 1.668 1.042 2.670 0.033
Anti-hyperglycaemic agent
Taking 45 (7.0) 103 (11.0)
Not taking 601 (93.0) 830 (89.0) 0.603 0.419 0.870 0.006
Diabetes mellitus
No 565 (77.5) 765 (82.0) 1.00
Yes 81 (12.5) 186 (18.0) 1.532 1.150 2.040 0.004
TC (mmol/l) 5.05 ± 1.00 5.43 ± 1.40 1.281 1.179 1.392 0.001
<5.17 363 (56.2) 361 (38.7) 1.00
≥5.17 283 (59.1) 571 (40.9) 2.029 1.655 2.487 0.001
HDL (mmol/l) 1.43 ± 0.44 1.24 ± 0.61 0.485 0.384 0.612 0.001
Normal§ 551 (85.3) 576 (61.8) 1.00
Low 95 (14.7) 356 (38.2) 3.585 2.779 4.625 0.001
FPG (mmol/l) 5.52 ± 1.37 5.91 ± 1.95 1.166 1.084 1.253 0.001
Normal 432 (68.7) 519 (57.2) 1.00
High 197 (31.3) 389 (42.8) 1.644 1.327 2.035 0.001
Alcohol
Not Taking 635 (98.3) 892 (95.6) 1.00
Taking 11 (1.7) 41 (4.4) 2.653 1.353 5.202 0.004
Hepatitis
No 546 (84.5) 844 (90.5)
Yes 100 (15.5) 89 (9.5) 0.576 0.424 0.781 0.001
§ ≥ 1.03 ( Male) and ≥ 1.30 (Female). ARV: Antiretroviral. Adjusted for age, gender, ethnicity, hypertension, diabetes mellitus, CD4, HIV RNA Load, TC, LDL, HDL, FPG,
alcohol consumption, smoking, liver disease, medication with agents including ARV (PI), b-blocker, anti-hyperglycemic. aOR Adjusted odds ratio.
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Table 3 Risk factors for increased low-density lipoprotein cholesterol (LDL-C) level in 1578 HIV subjects (normal = 1023,
increased LDL-C = 555) on ARV medication
Characteristics Normal Increased LDL aOR 95.0 C.I. for OR p-value
Mean ± S.D. Mean ± S.D. Lower Upper
N (%) N (%)
Ethnicity
Malay 703 (69.3) 317 (57.4) 1.00
Chinese 214 (21.1) 175 (31.7) 0.551 0.434 0.701 0.001
Indian 98 (9.7) 60 (10.9) 0.749 0.513 1.093 0.134
Hypertension
No 785 (80.5) 400 (74.6) 1.00
Yes 190 (19.5) 136 (25.4) 1.405 1.093 1.805 0.008
TG (mmol/l) 2.54 ± 2.00 2.14 ± 1.14 0.858 0.800 0.920 0.001
<3.36 413 (40.4) 233 (42.0) 1.00
≥3.36 609 (59.6) 322 (58.0) 0.937 0.760 1.156 0.545
TC (mmol/l) 4.74 ± 1.00 6.26 ± 1.09 6.468 5.319 7.866 0.001
<5.17 705 (69.0) 19 (3.4)
>5.17 317 (31.0) 536 (96.6) 2.620 2.399 2.861 0.001
HDL (mmol/l) 1.31 ± 0.65 1.33 ± 0.33 1.049 0.876 1.257 0.602
Low 349 (34.1) 101 (18.2) 1.00
Normal§ 673 (65.9) 454 (81.8) 2.331 1.813 2.997 0.001
Hepatitis
No 882 (86.2) 507 (91.4) 1.00
Yes 141 (13.8) 48 (8.6) 0.592 0.419 0.836 0.003
§ ≥1.03 (Male) and ≥1.30 (Female). Adjusted for age, gender, ethnicity, hypertension, diabetes mellitus, CD4, HIV RNA Load, TC, TG, HDL, FPG, alcohol
consumption, smoking, liver disease, medication with agents including ARV (PI), b-blocker, anti-hyperglycemic. aOR Adjusted odds ratio.
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increased level of TC ≥ 5.17 (OR = 1.867, 95% CI = 1.498–
2.327) and ARV therapy with PIs (OR = 1.449, 95% CI =
1.037–2.024). Beside this study showed that being Indian
(OR = 0.570, 95% CI = 0.386–0.842), higher level of TG
(OR = 0. 693, 95% CI = 646–0.745) and having hepatitis
disease (OR = 0.630, 95% CI = 0.459–0.865) significantly
decreased the risk of low HDL level (p < 0.001). Age,
gender, hypertension, b-blocker, diabetes mellitus, FPG,
alcohol consumption, smoking were not associated with
low level of HDL.
Risk factors of raised FPG
Table 6 present those significant factors (p < 0.001)
which increase the risk of hyperglycemia including in-
creasing age (OR = 1.048, 95% CI = 1.036–1.059), having
hypertension (OR = 1.954, 95% CI = 1.522–2.508) and
higher level of TG (OR = 1.130, 95% CI = 1.066–1.199).
On the other hand being female (OR = 0.711, 95%
CI = 0.543- 0.931), not taking b-blocker (OR = 0.585,
95% CI = 0.379- 0.902), not taking anti-hyperglycemic
agents (OR = 0.164, 95% CI = 0.110–0.244) and not hav-
ing diabetes mellitus (OR = 0.330, 95% CI = 0.249–0.438)significantly protect the subjects from increased fasting
plasma glucose (p < 0.001).
Differences in ethnicity, using PI, CD4 viral load
level, LDL, TC, HDL, alcohol consumption and smok-
ing were not increased the risk of high FPG significantly
(p > 0.05).
Discussion
This primarily and large study of HIV infected subject
on ART found that dyslipidemia was a high predomin-
ant disorder. Majority of the subjects (60%) had in-
creased levels of TG or TC while a less proportions of
subject affected with high levels of LDL (35.1%) and
FPG (38.2%) and, low HDL level (28.7%). Some studies
in Thailand reported a similar rate of dyslipidemia at
53.6% and 88% [38,50]. Other studies from other devel-
oping countries showed similar results oh high preva-
lence lipid abnormalities rate of more than 76% [35]
from Tanzania, 82.3% [19] from Southern Ethiopia, 20-
100% from India [7,41].
Disturbances in level of triglyceride and total choles-
terol were more prevalent than HDL and LDL in this
study. Generally increases in TG and TC level are mainly
Table 4 Risk factors for increased total cholesterol (TC) level in 1582 HIV subjects (normal = 725, increased TC = 857)
on ARV medication
Characteristics Normal Increased TC aOR 95.0 C.I. for OR p-value
Mean ± S.D. Mean ± S.D. Lower Upper
N (%) N (%)
Age (year)
Mean ± SD 43.87 ± 10.09 44.88 ± 9.65 1.010 1.000 1.021 0.043
Gender
Male 608 (83.9) 665 (77.6) 1.00
Female 117 (16.1) 192 (22.4) 1.500 1.163 1.936 0.002
Hypertension
No 565 (81.6) 621 (75.5) 1.00
Yes 127 (18.4) 201 (24.5) 1.440 1.122 1.848 0.004
ARV medication
Without PI 649 (91.3) 731 (87.0) 1.00
With PI 62 (8.7) 109 (13.0) 1.561 1.123 2.169 0.008
Viral load (copies/mL)
≥20 115 (15.9) 98 (11.4) 1.00
<20 610 (84.1) 759 (88.6) 1.460 1.093 1.951 0.010
LDL (mmol/l) 2.37 ± 0.72 3.57 ± 0.97 6.977 5.705 8.534 0.001
<3.36 705 (97.4) 317 (37.2) 1.00
≥3.36 19 (2.6) 536 (62.8) 20.150 12.928 31.406 0.001
TG (mmol/l) 2.03 ± 1.29 2.73 ± 2.09 1.312 1.220 1.412 0.001
<5.17 363 (50.1) 283 (33.1) 1.00
≥5.17 361 (49.9) 571 (66.9) 2.029 1.655 2.487 0.001
HDL (mmol/l) 1.31 ± 0.70 1.32 ± 0.40 1.034 0.866 1.234 0.714
Low 256 (35.6) 196 (22.9) 1.00
Normal§ 466 (64.4) 661 (77.1) 1.867 1.498 2.327 0.001
Hepatitis
No 612 (84.4) 781 (91.1) 1.00
Yes 113 (15.6) 76 (8.9) 0.527 0.387 0.718 0.001
§ ≥1.03 (Male) and ≥1.30 (Female). ARV: Antiretroviral. Adjusted for age, gender, ethnicity, hypertension, diabetes mellitus, CD4, HIV RNA Load, TG, LDL, HDL, FPG,
alcohol consumption, smoking, liver disease, medication with agents including ARV (PI), b-blocker, anti-hyperglycemic. aOR Adjusted odds ratio.
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http://www.biomedcentral.com/1471-2458/13/758attributed to treatment with PIs. The multiple mechan-
ism of PIs in developing lipid and glucose abnormal-
ities include reduction in catabolism and increase in
production of very low density lipoprotein [51,52], im-
paired catabolism of fatty free acid [53], increased syn-
thesis of triglyceride in liver [54], decreased expression
of LDL receptors [55], interference with the intercel-
lular process regulating glucose and lipid metabolism
in insulin-response tissue [56]. Other relevant factors
comprise of aging, abdominal obesity, diabetes, lifestyle,
gender and ethnic differences, type and length of time on
ARV regimen can result in various incidence/prevalence
of lipid and glucose abnormalities.
Aging, race and gender differences are well-known irre-
versible risk factors for metabolic abnormalities. Elderlypopulation has lipid and glucose metabolism changes
due to liver cell dysfunctions [57]. The beneficial effect of
endogenous estrogen women before menopause causes
less lipid abnormalities [58]. Similar to this study Richter
and colleagues [59] in a cohort study indicated that
age, treatment with PI and male gender were risks for
dyslipidemia. Some studies [60,61] which were conducted
in the United State also revealed that race/ethnicity was a
highly significant predictor of plasma lipids. In a study
the increased lipid level was significantly less associated
with Malay and Chinese’s race [62]. One of the possible
explanations may be due to the lower prevalence of abdom-
inal obesity among Malay and Chinese HIV patients [62].
In the present study alcohol consumption was associated
with high level of TG. As the recognized dietary risk for
Table 5 Risk factors for low high-density lipoprotein (HDL) level in 1582 HIV subjects (normal = 1128, low HDL = 454)
on ARV medication
Characteristics Normal Low HDL aOR 95.0 C.I. for OR p-value
Mean ± S.D. Mean ± S.D. Lower Upper
N (%) N (%)
Ethnicity
Malay 105 (23.3) 285 (25.4) 1.00
Indian 62 (13.7) 96 (8.6) 0.570 0.386 0.842 0.009
Chinese 284 (27.8) 739 (72.2) 1.753 1.187 2.589 0.005
ARV medication
Without PI 382 (86.2) 998 (90.1) 1.00
With PI 61 (13.8) 110 (9.9) 1.449 1.037 2.024 0.029
Anti-hyperglycaemic Agents
Not taking 57 (12.6) 91 (8.1) 1.00
Taking 397 (87.4) 1037 (91.9) 1.636 1.152 2.323 0.006
Viral Load (copies/mL)
<20 391 (86.1) 979 (86.8) 1.00
>20 63 (13.9) 149 (13.2) 0.945 0.688 1.297 0.724
CD4 (cells/mm3)
<200 25 (5.6) 90 (8.0) 1.00
≥200 419 (94.4) 1029 (92.0) 0.682 0.432 1.078 0.099
TG (mmol/l) 2.08 ± 1.37 3.23 ± 2.39 0.693 0.646 0.745 0.001
<5.17 95 (21.1) 551 (48.9) 1.00
≥5.17 356 (78.9) 576 (51.1) 0.279 0.216 0.360 0.001
LDL (mmol/l) 3.17 ± 1.01 2.64 ± 1.05 1.709 1.516 1.926 0.001
<3.36 349 (77.6) 673 (59.7) 1.00
≥3.36 101 (22.4) 454 (40.3) 2.331 1.813 2.997 0.001
TC (mmol/l)
<5.17 258 (56.8) 466 (41.3) 1.00
≥5.17 196 (43.2) 661 (58.7) 1.867 1.498 2.327 0.001
Hepatitis
No 383 (84.4) 1010 (89.5) 1.00
Yes 71 (15.6) 118 (10.5) 0.630 0.459 0.865 0.004
Adjusted for age, gender, ethnicity, hypertension, diabetes mellitus, CD4, HIV RNA Load, TC, TG, LDL, FPG, alcohol consumption, smoking, liver disease, medication
with agents including ARV (PI), b-blocker, anti-hyperglycemic. aOR Adjusted odds ratio, ARV Antiretroviral.
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http://www.biomedcentral.com/1471-2458/13/758high TG, alcohol is rich in calorie and disturb the liver
function, the human organ which contributes in metabolize
of the nutrients [63], thus it can be stored in body as fat
and increase in blood as TG. It is important to stress that
the data are derived from a male population mostly and
that their relevance is mainly to be referred to male sex.
Interestingly the effect of some risk or protective factors on
lipid and glucose can be explained by their indirect and inter-
mediary role. In this study higher CD4 cell count was a risk
factor for high TG while viral load level < 20 (copies/mm3)
raised the risk of high TC. ARV medications boost immune
system by increasing in CD4 cells and diminishing HIV
vial load thus the effect of ARV medication on lipids wasseen through the raised CD4 and decreased viral load [64].
We also found that treatment with anti-hyperglycemic agents
was a significant associated risk for high TG and low HDL
level. Since diabetic patients have more lipid abnormalities
thus taking anti-hyperglycaemic medication can make a con-
nection between diabetes and these lipid disorders indirectly
[65]. Approximately 14% of our population had hepatitis as
liver diseases who had lowered risk of lipid disorders and in-
creased possibility of high FPG. On the hepatitis virus nature,
some studies found that hepatitis viral replication during its
metabolic processes can drop in lipid levels by interrupting
cholesterol synthesis and using host lipids for replication, de-
creasing circulating lipids, and clearance of the virus results
Table 6 Risk factors for increased fasting plasma glucose (FPG) level in 1540 HIV subjects (normal = 952,
increased FPG = 588) on ARV medication
Characteristics Normal Hypertensive aOR 95.0 C.I. for OR p-value
Mean ± S.D. Mean ± S.D. Lower Upper
N (%) N (%)
Age (year)
Mean ± SD 42.79 ± 9.68 47.17 ± 9.56 1.048 1.036 1.059 0.001
Gender
Male 751 (78.9) 494 (84.0) 1.00
Female 201 (21.1) 94 (16.0) 0.711 0.543 0.931 0.013
Hypertension
No 754 (82.6) 398 (70.8) 1.00
Yes 159 (17.4) 164 (29.2) 1.954 1.522 2.508 0.001
b-Blocker
taking 43 (4.5) 44 (7.5) 1.00
Not Taking 909 (95.5) 544 (92.5) 0.585 0.379 0.902 0.014
Anti-hyperglycaemic
Taking 35 (3.7) 111 (18.9) 1.00
Not taking 917 (96.3) 477 (81.1) 0.164 0.110 0.244 0.001
Diabetes mellitus
Yes 96 (10.1) 149 (25.3) 1.00
No 856 (89.9) 439 (74.7) 0.330 0.249 0.438 0.001
TG (mmol/l) 2.25 ± 1.74 2.65 ± 1.82 1.130 1.066 1.199 0.001
<5.17 432 (45.4) 197 (33.6) 1.00
≥5.17 519 (54.6) 389 (66.4) 1.644 1.327 2.035 0.001
Hepatitis
No 857 (90.0) 498 (84.7) 1.00
Yes 95 (10.0) 90 (15.3) 1.630 1.197 2.220 0.002
Adjusted for age, gender, ethnicity, hypertension, diabetes mellitus, CD4, HIV RNA Load, TC, TG, LDL, HDL, alcohol consumption, smoking, liver disease, medication
with agents including ARV (PI), b-blocker, anti-hyperglycemic. aOR Adjusted odds ratio.
Hejazi et al. BMC Public Health 2013, 13:758 Page 9 of 11
http://www.biomedcentral.com/1471-2458/13/758in rebound increase of lipid levels [66,67]. Since liver is the
main body organ for balancing plasma glucose, damage to
the liver cell by hepatitis virus causes disturbed liver function
and insulin production [68] thus it is expected the elevated
FPG during hepatitis infection.Limitations of the study
Comprehensive blood lipid and glucose evaluation were
not assessed in this study just for those with current
tests (year 2012). Also inability of assessment of an-
thropometrics including waist circumference, body mass
index (BMI) and body fat percentage, the cross-sectional
nature of the study, small number of female as well Indian
subjects, and lack of ARVnaïve or HIV negative subjects as
controls, absence of previous published studies in lipid ab-
normalities among Malaysian population with HIV/AIDS
in order to comparison with the present study were con-
sidered as other limitations in this study.Conclusion
Our study indicates a high proportion of HIV-infected
patients receiving ARV medication met the criteria for
dyslipidemia. Also treatment with protease inhibitorswas
responsible and risk factor for high prevalence of lipid
profile disorders. Therefore, it is crucial to evaluate and
monitor these abnormalities before initiation and during
Highly Active Antiretroviral therapy (HAART) to moni-
tor any rising trends. It should be mentioned that study
of metabolic abnormalities among ARV naive patients
for assessment of independent effect of HIV itself on
lipid and glucose is considerable due to the importance
of the choice of type ARV agents in combination therapy
as HAART.Moreover based on our results; assessment
of long-term effects of ARVagents on lipid abnormal-
ities is suggested. Also investigations and implementation
programs on prevention and treatment of lipid abnormal-
ities by the way of lifestyle and nutritional modification
strategies are optional.
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